NLRP3 and atrial fibrillation: Collectively, these data underscore the role of inflammasome-mediated innate immune pathways—specifically those involving NLRP3 and AIM2—as central molecular effectors of AtCM and AF, and highlight their potential as therapeutic targets in AF management.